Endostar combined with chemotherapy on the multiple kinds of advanced malignancies

Objective:To observe prospectively and systematically the efficacy and safety of rh-endostatin injection(YH-16,Endostar),a new molecular targeted anti-tumor agent,combined with the chemotherapy on the multiple kind of advanced malignancies.Methods:Endostar combined with chemotherapy were administrated to 36 malignant cases of stage Ⅳ(including 9 cases with non-small cell lung cancer,27cases with other cancers)confirmed by histopathology or cytopathology.15mg endostar solved in 500ml of normal saline was slow intravenously dropped from day 1 to day 14,repeated after 7 days later.The chemotherapy agents which was not used before or not cross-resistant to pre-chemotherapeutic agents were selected to be given simultaneously.The regimen was repeated every 21days.The efficacy was evaluated strictly after 2 cycles according to RECIST criteria,and quality of life(QOL)was evaluated according to Karnofsky scores.Otherwise safety was evaluated after 1 cycle according to NCI CTC 3.0 version criteria.Results:Thirty cases were evaluable for efficacy among the total 36 cases that were capable of safety evaluation.Totally 83 cycles were completed and mean cycle was 2.3.Among 30 evaluable cases,there were 4 cases achieved PR,17 cases of SD,and 9 cases of PD.The objective response rate(RR)was 13.3%(4/30)and disease control rate(DCR)was 70.0%(21/30).The quality of life(QOL)were improved on 11 cases(36.7%),stabled on 13 cases(43.3%),and decreased on 8 cases(20.0%).The occurrence rates of G3/4 toxicities were low,including neutropenia(1/36,2.7%),thrombocytopenia(3/36,8.3%),nausea /vomiting(1/36,2.7%),and diarrhea(1/36,2.7%).These toxicities were mainly related with the chemotherapy agents.Conclusion:The QOL of patients with multiple kinds of advanced malignancies may be improved by endostar combined with the related chemotherapy.Maybe there have synergetic effects of endostar with some of cytotoxic agents.It is worthy of clinical generalization and further clinical observation.